<DOC>
	<DOCNO>NCT01001780</DOCNO>
	<brief_summary>Chronic graft-versus-host disease ( GvHD ) severe , life threaten complication get bone marrow stem cell transplant . It cause certain cell donor attack cell . The usual treatment , prednisone cyclosporine , n't work well chronic GVHD . This research do determine combination chemotherapeutic immunosuppressive , drug pentostatin , cyclophosphamide monoclonal antibody rituximab , use `` PCR '' combination prove useful treatment certain patient chronic GvHD ( namely unlikely respond standard therapy ) .</brief_summary>
	<brief_title>Pentostatin , Cyclophosphamide Plus Rituximab ( PCR ) Therapy Poor-Prognosis Chronic Graft-Versus-Host Disease</brief_title>
	<detailed_description>As , chronic GvHD either respond , expect , respond standard immunosuppressive treatment chronic GvHD . These standard treatment give relatively low dos long interval . Thus , study test alternate strategy , use intensive , combine therapy PCR combination determine improve outcome . PENTOSTATIN , CYCLOPHOSPHAMIDE plus RITUXIMAB ( `` PCR '' ) FDA-approved drug chemotherapy certain lymphomas/leukemias , although use separately treat patient chronic GvHD , approve immunosuppressant treatment chronic GvHD , either separately together . We study `` PCR '' combination 9-17 patient chronic GvHD refractory , expect respond standard therapy . Response measure achievement document complete remission ( i.e. , full resolution symptom sign ) , thus , shorten total duration immunosuppressive ( anti-chronic GvHD ) therapy . This latter effect may reduce overall infection .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>Diagnosis chronic GvHD require least one diagnostic and/or least one distinctive manifestation . The latter must confirm pertinent biopsy , laboratory test , radiology another organ . ( See 19.11 detail ) Confirmation active chronic GvHD desire may feasible . Age &gt; /= 18 yr . No gender ethnic restriction . Previously untreated chronic GvHD Up 15 day ' single agent therapy may give patient consider `` previouslyuntreated '' , provide progression observe . Vogelsang score20 &gt; /= 2 If patient progress prednisone &gt; /= 0.5 mg/kg/day ( equivalent ) treatment acute GvHD develop chronic GvHD , may consider candidate irrespective Vogelsang Score . Prior therapy . Patients must receive prednisone &gt; /= 0.5 mg/kg/day plus one ( ) follow second agent : tacrolimus , cyclosporine , sirolimus , mycophenolate . All second subsequent failure eligible . Special circumstance : involvement `` critical organ '' . In case , progressive involvement use initial therapy suffice eligibility criterion irrespective Vogelsang score . Previous history severe adverse reaction either study agent . Prior exposure alone agents PCR contraindication , Use one agent PCR treat GvHD exclude patient entry . Serious active infection ( especially hepatitis B C ) respond therapy . Active malignancy and/or requirement immunomodulation treatment malignancy . Hematologic abnormality : WBC &lt; 3.0 K/uL , ANC &lt; 1.0 K/uL , Hgb &lt; 8.0 g/dL , platelet &lt; 50.0 K/uL . Nonhematologic toxicities* : *Renal . Measured creatinine clearance &lt; 35 ml/min concomitant need dialysis . *Pulmonary . DLCO &lt; 40 % , FEV1 , 50 % . *Hepatic . LFT ( measure AST , ALT , T.bili ) One level find &gt; 3 x normal . Other . History significant comorbid disease felt make propose therapy excessively risky . Psychiatric . Patients uncompensated severe psychiatric illness would preclude sign necessary consent form compliant . Compliance . Patients unlikely adhere study procedure and/or unable unwilling return necessary followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Graft versus Host Disease</keyword>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplant</keyword>
</DOC>